Skip to main content
Clinical Trials/NCT05600725
NCT05600725
Completed
Not Applicable

Novel Pacing Modality to Initiate Favorable Cardiac Remodeling in Heart Disease

Denise Hodgson-Zingman1 site in 1 country5 target enrollmentNovember 2, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiomyopathies
Sponsor
Denise Hodgson-Zingman
Enrollment
5
Locations
1
Primary Endpoint
Quality of life/symptom score
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This project utilizes a novel cardiac pacing approach hypothesized to initiate beneficial cardiac conditioning and remodeling over a period of time.

Detailed Description

The project studies subjects with non-ischemic cardiomyopathy who have a pacing device already implanted. Subjects randomized to the pacing intervention versus a sham intervention will be compared for various symptomatic, functional and other outcomes. Each subject will undergo baseline quality of life/symptom questionnaires and clinical testing for cardiac functional/structural effects and exercise tolerance, then the intervention vs. sham (subjects blinded to their category), followed by repeat questionnaires and clinical testing. Medical record review will be undertaken to establish demographic variables, baseline and follow up testing results.

Registry
clinicaltrials.gov
Start Date
November 2, 2022
End Date
February 28, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Denise Hodgson-Zingman
Responsible Party
Sponsor Investigator
Principal Investigator

Denise Hodgson-Zingman

Professor

University of Iowa

Eligibility Criteria

Inclusion Criteria

  • Non-Ischemic Cardiomyopathy
  • Ejection Fraction \</= 35% despite at least 3 months stable standard medical management
  • New York Heart Association Class II-III symptoms
  • Dual chamber implantable cardioverter defibrillator in place or Biventricular ICD in place (over 3 months old)
  • Normal Atrioventricular conduction or Biventricular ICD
  • QRS \< 120 msec (inherent conduction or paced with BiV ICD)
  • Exclusion criteria:
  • Age \< 18 years
  • Inability to ambulate safely
  • Congenital or primary valve disease

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Quality of life/symptom score

Time Frame: 4 weeks after start of the protocol

Minnesota Living with Heart Failure Score (range 0-105, higher scores indicate worse quality of life)

Secondary Outcomes

  • six minute walk(at the time of enrollment, and at 4 weeks after start of the protocol)
  • diastolic blood pressure(every 5 minutes during intervention/sham in weeks 1-4 of the protocol)
  • systolic blood pressure(every 5 minutes during intervention/sham in weeks 1-4 of the protocol)
  • MACE(4 weeks and 4 months after start of the protocol)
  • Oxygen saturation(every 5 minutes during intervention/sham in weeks 1-4 of the protocol)
  • cardiac output(every 5 minutes during intervention/sham in weeks 1-4 of the protocol)

Study Sites (1)

Loading locations...

Similar Trials